Apidra Solostar Pen

• Improvement of glycemic control in adults and pediatric patients with diabetes mellitus

Adult Dose (Subcutaneous):

• Diabetes Mellitus: 0.5-1 unit/kg/day (individualized)
• Inject within 15 minutes before a meal or within 20 minutes after starting a meal
• Should generally be used in regimens with intermediate or long-acting insulin
• Hepatic impairment: Dose reduction may be needed

Child Dose (Type 1, 4-17 years): 0.8-1.2 units/kg/day during growth spurts; otherwise adult dosing (0.5-1 unit/kg/day)

Side Effects:

• Hypoglycemia
• Allergic reactions
• Injection site reactions
• Lipodystrophy
• Pruritus
• Rash
• Weight gain

Use in Pregnancy: Category C; animal studies have shown adverse effect on fetus; no adequate human studies; potential benefits may warrant use despite potential risks.

Precautions:

• Your ability to drive may be affected if blood sugar is too low or too high
• Hypoglycemia may be life-threatening; increase frequency of glucose monitoring with changes to insulin dosage, coadministered glucose lowering medications, meal pattern, physical activity
• Caution in patients with renal impairment or hepatic impairment or hypoglycemia unawareness
• Hypoglycemia due to medication errors: Check insulin labels before injection
• Hypokalemia: Monitor potassium levels in patients at risk
• Fluid retention and heart failure can occur with concomitant use of TZDs

Overdose: Excess insulin may cause hypoglycemia and, particularly when given intravenously, hypokalemia; mild episodes treated with oral glucose; severe episodes (coma, seizure, neurologic impairment) treated with IM/SC glucagon or IV glucose; hypokalemia must be corrected appropriately.